TG Therapeutics, Inc.
TGTX
Rang in Aktien
#2355
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Aktienkurs
$54.70
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$8.37B
Veränderung (1 Tag)
2.63%
Veränderung (1 Jahr)
55.31%
Land
US
Handel TG Therapeutics, Inc. (TGTX)
Kategorie
Healthcare
Gewinn für TG Therapeutics, Inc. (TGTX)
Gewinn im Jun 2026 TTM: $101.60M
Laut den aktuellen Finanzberichten von TG Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $101.60M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $13.06M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-223.81M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von TG Therapeutics, Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $101.60M | 296.96% |
| 2024 | $25.59M | 95.94% |
| 2023 | $13.06M | -105.84% |
| 2022 | $-223.81M | -35.70% |
| 2021 | $-348.10M | 24.60% |
| 2020 | $-279.38M | 61.61% |
| 2019 | $-172.87M | -0.35% |
| 2018 | $-173.48M | 46.43% |
| 2017 | $-118.48M | 51.40% |
| 2016 | $-78.25M | 24.31% |
| 2015 | $-62.95M | 12.85% |
| 2014 | $-55.78M | 172.39% |
| 2013 | $-20.48M | -20.79% |
| 2012 | $-25.85M | 2,807.86% |
| 2011 | $-889.07K | -166.04% |
| 2010 | $1.35M | -147.54% |
| 2009 | $-2.83M | -39.27% |
| 2008 | $-4.66M | -61.25% |
| 2007 | $-12.03M | 20.31% |
| 2006 | $-10.00M | -48.32% |
| 2005 | $-19.35M | 218.71% |
| 2004 | $-6.07M | -15.91% |
| 2003 | $-7.22M | 363.40% |
| 2002 | $-1.56M | -12.31% |
| 2001 | $-1.78M | -69.86% |
| 2000 | $-5.90M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 5,091.88% |
US
|
|
| $-3.09B | -3,138.42% |
US
|
|
| $-4.02B | -4,052.99% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,819.95% |
NL
|
